---
title: 'Manufacturing Daily Summary: What Happened on November 18, 2026'
headline: mAbxience backs OncoPrecision and will make material for its cancer candidate
description: Other manufacturing work spans engineered TIL production, rapid sterility
  testing for cell therapies and a biodegradable purification resin evaluated in four
  applications.
url: https://thebench.bio/news/manufacturing/2026-11-18
topic: manufacturing
date: '2026-11-18'
covers:
- '2026-11-18'
date_published: '2026-11-19T00:03:23Z'
date_modified: '2026-11-19T00:03:23Z'
tags:
- Manufacturing
- Funding
- Industry
sources: 4
publisher: TheBench.Bio
---

# Manufacturing Daily Summary: What Happened on November 18, 2026

**mAbxience backs OncoPrecision and will make material for its cancer candidate**

Other manufacturing work spans engineered TIL production, rapid sterility testing for cell therapies and a biodegradable purification resin evaluated in four applications.

## Today in brief

mAbxience invested in OncoPrecision and agreed to develop ONC001’s antibody component and make GMP-grade material for a planned Phase 1 trial. [1]

Separate teams are testing automated production of engineered TILs, a phased sterility-testing route for cell therapies and a biodegradable resin across four purification applications. [2] [3] [4]

## mAbxience backs OncoPrecision’s ONC001 development

mAbxience made a strategic investment in OncoPrecision and agreed to develop and manufacture material for ONC001, a preclinical antibody-drug conjugate. [1] The work covers the antibody component, from cell-line work through process and analytical development, followed by GMP-grade production for a planned Phase 1 trial. [1]

The companies describe ONC001 as a CD64-directed candidate targeting leukemic monocytes and tumor-associated macrophages, with monocytic acute myeloid leukemia and chronic myelomonocytic leukemia as lead indications. [1] mAbxience CEO Jurgen Van Broeck will join OncoPrecision’s board as an observer. [1]

## Also worth knowing

- Terumo BCT, TrAMPoline Pharma and the University of Colorado are using the Quantum Flex Cell Expansion System to automate production of genetically engineered tumor-infiltrating lymphocytes. Early work will compare automated expansion with the current method. [2]
- Athena Stathoulis and colleagues proposed a three-stage alternative sterility-testing pathway for cell therapies, combining parallel testing and conditional release with post-infusion compendial testing as a safeguard. [3]
- Medium Well and its partners evaluated biodegradable BioResin in four protein-purification applications. The resin maintained stable performance through as many as 100 cleaning cycles. [4]

## The day in numbers

- **100 cleaning cycles**: BioResin maintained stable performance through this many cycles under the reported regimen. [4]
- **14 days versus 24–72 hours**: Athena Stathoulis said the standard USP \<71\> sterility test takes 14 days, while fresh CAR T products may need infusion within 24 to 72 hours. [3]

## Also published

- [Tuning Extracellular Vesicle Production and Analytics for Compliance](<https://www.genengnews.com/topics/bioprocessing/tuning-extracellular-vesicle-production-and-analytics-for-compliance/>), GEN

## Sources

1. [mAbxience Backs OncoPrecision ADC With Investment, Manufacturing Deal](<https://www.biopharminternational.com/view/mabxience-oncoprecision-onc001-adc-manufacturing-investment-agreement>), BioPharm International, 2026-11-18
2. [The Advent of Automated, Gene-Engineered TIL Manufacturing](<https://www.genengnews.com/topics/bioprocessing/the-advent-of-automated-gene-engineered-til-manufacturing/>), GEN, 2026-11-18
3. [Growing Apart: Culture-Based Sterility Test Alternatives](<https://www.genengnews.com/topics/bioprocessing/growing-apart-culture-based-sterility-test-alternatives/>), GEN, 2026-11-18
4. [Enabling Sustainable and Cost-Effective Downstream Processing for the Next Generation of Industrial Biotechnology](<https://www.bioprocessintl.com/chromatography/enabling-sustainable-and-cost-effective-downstream-processing-for-the-next-generation-of-industrial-biotechnology>), BioProcess International, 2026-11-18

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.biopharminternational.com/view/mabxience-oncoprecision-onc001-adc-manufacturing-investment-agreement>
[2]: <https://www.genengnews.com/topics/bioprocessing/the-advent-of-automated-gene-engineered-til-manufacturing/>
[3]: <https://www.genengnews.com/topics/bioprocessing/growing-apart-culture-based-sterility-test-alternatives/>
[4]: <https://www.bioprocessintl.com/chromatography/enabling-sustainable-and-cost-effective-downstream-processing-for-the-next-generation-of-industrial-biotechnology>
